Advertisement

Neuromodulation Interventions: ECT and rTMS – Work-Up, Preparation, and Posttreatment Care + Ketamine in Inpatient Psychiatry

  • Lisa A. McMurray
  • Barbara Deren
Chapter

Abstract

An inpatient psychiatric unit is often the setting wherein rapid treatment can be safely and efficiently administered for the most intractable and severe psychiatric illnesses. Electroconvulsive therapy (ECT) is an effective intervention for bipolar and major depressive disorders. There are many reasons to consider ECT. For example, aging and medically compromised patients may be unable to tolerate adequate pharmacotherapy for depressive and other disorders, and ECT remains a safe alternative. Suicide rates in geriatric populations are high, particularly in men, and older patients frequently attempt suicide with lethal means (Chap. 8: Suicide). The hospital or partial hospital setting may provide the necessary precautions and treatments for risks of dehydration, inanition, medical comorbidity, functional decline, frailty, and suicidality, in addition to addressing the need for rapid clinical response. There is also evidence emerging to support the use of ECT for the Non-Cognitive Symptoms (NCS) and Neuropsychiatric Symptoms (NPS) of Major Neurocognitive Disorders (MNCD) (Chap. 6: Major neurocognitive disorer MNCD with Behavioral Disturbance).

Newer treatments, such as repetitive transcranial magnetic stimulation (rTMS), are showing promising results and excellent tolerability. rTMS is administered to awake patients, thereby avoiding the associated risks of general anesthesia. Evidence of its efficacy for major depressive episodes is less robust than that for ECT, and it is not yet available and/or covered by insurance in many settings. Also, the place of rTMS on the inpatient unit has yet to be established, as current treatment protocols may require 4–6 weeks to complete.

Intravenous (IV) infusion of ketamine at sub-anesthetic doses is an investigational treatment for depression and suicidal ideation, but has not yet been studied extensively in older adults. More recently, a formulation of esketamine, administered intranasally, has been approved by the FDA for treatment resistant depression (TRD). To date, no studies of this formulation in the geriatric population could be found. If research supports its safety and efficacy in the general adult population, ketamine may eventually be found to have utility in the rapid treatment of suicidal ideation and treatment-resistant depression in the inpatient geriatric psychiatry setting as well.

ECT remains the definitive treatment when there is limited improvement with other modalities, when pharmacotherapy is poorly tolerated, and when psychiatric/behavioral symptoms require a rapid response.

Keywords

Electroconvulsive therapy ECT Repetitive transcranial magnetic stimulation rTMS Ketamine Late-life depression Inpatient Neuropsychiatric symptoms Behavioral disturbance 

References

  1. 1.
    Yazgan IC, Greenwald BS, Kremen NJ, Strach J, Kramer-Ginsberg E. Geriatric psychiatry versus general psychiatry inpatient treatment of the elderly. Am J Psychiatry. 2004;161(2):352–5.CrossRefGoogle Scholar
  2. 2.
    Knochel C, Alves G, Friedrichs B, Schneider B, Schmidt-Rechau A, Wenzler S, et al. Treatment-resistant late-life depression: challenges and perspectives. Curr Neuropharmacol. 2015;13(5):577–91.CrossRefPubMedPubMedCentralGoogle Scholar
  3. 3.
    Roose SP, Schatzberg AF. The efficacy of antidepressants in the treatment of late-life depression. J Clin Psychopharmacol. 2005;25(4 Suppl 1):S1–7.CrossRefPubMedPubMedCentralGoogle Scholar
  4. 4.
    Kerner N, Prudic J. Current electroconvulsive therapy practice and research in the geriatric population. Neuropsychiatry (London). 2014;4(1):33–54.CrossRefGoogle Scholar
  5. 5.
    Galvez V, Ho KA, Alonzo A, Martin D, George D, Loo CK. Neuromodulation therapies for geriatric depression. Curr Psychiatry Rep. 2015;17(7):59.CrossRefPubMedGoogle Scholar
  6. 6.
    McDonald WM. Neuromodulation treatments for geriatric mood and cognitive disorders. Am J Geriatr Psychiatry. 2016;24(12):1130–41.CrossRefPubMedGoogle Scholar
  7. 7.
    aan het Rot M, Collins KA, Murrough JW, Perez AM, Reich DL, Charney DS, et al. Safety and efficacy of repeated-dose intravenous ketamine for treatment-resistant depression. Biol Psychiatry. 2010;67(2):139–45.CrossRefGoogle Scholar
  8. 8.
    Nasreddine ZS, Phillips NA, Bedirian V, Charbonneau S, Whitehead V, Collin I, et al. The Montreal Cognitive Assessment, MoCA: a brief screening tool for mild cognitive impairment. J Am Geriatr Soc. 2005;53(4):695–9.CrossRefPubMedPubMedCentralGoogle Scholar
  9. 9.
    Montgomery SA, Asberg M. A new depression scale designed to be sensitive to change. Br J Psychiatry. 1979;134:382–9.CrossRefPubMedPubMedCentralGoogle Scholar
  10. 10.
    Spellman T, Peterchev AV, Lisanby SH. Focal electrically administered seizure therapy: a novel form of ECT illustrates the roles of current directionality, polarity, and electrode configuration in seizure induction. Neuropsychopharmacology. 2009;34(8):2002–10.CrossRefPubMedPubMedCentralGoogle Scholar
  11. 11.
    Lefaucheur JP, Andre-Obadia N, Antal A, Ayache SS, Baeken C, Benninger DH, et al. Evidence-based guidelines on the therapeutic use of repetitive transcranial magnetic stimulation (rTMS). Clin Neurophysiol. 2014;125(11):2150–206.CrossRefPubMedGoogle Scholar
  12. 12.
    Dombrovski AYM, Benoit H. ECT: the preferred treatment for severe depression in late life. Int Psychogeriatr. 2006;19(01):10–4.CrossRefGoogle Scholar
  13. 13.
    Philibert RA, Richards L, Lynch CF, Winokur G. Effect of ECT on mortality and clinical outcome in geriatric unipolar depression. J Clin Psychiatry. 1995;56(9):390–4.PubMedPubMedCentralGoogle Scholar
  14. 14.
    Glass OM, Forester BP, Hermida AP. Electroconvulsive therapy (ECT) for treating agitation in dementia (major neurocognitive disorder) – a promising option. Int Psychogeriatr. 2017;29(5):717–26.CrossRefGoogle Scholar
  15. 15.
    Isserles M, Daskalakis ZJ, Kumar S, Rajji TK, Blumberger DM. Clinical effectiveness and tolerability of electroconvulsive therapy in patients with neuropsychiatric symptoms of dementia. J Alzheimers Dis. 2017;57(1):45–51.CrossRefPubMedGoogle Scholar
  16. 16.
    Fink M. What was learned: studies by the consortium for research in ECT (CORE) 1997–2011. Acta Psychiatr Scand. 2014;129(6):417–26.CrossRefPubMedGoogle Scholar
  17. 17.
    Greenberg RM, Kellner CH. Electroconvulsive therapy: a selected review. Am J Geriatr Psychiatry. 2005;13(4):268–81.CrossRefPubMedGoogle Scholar
  18. 18.
    Petrides G, Fink M, Husain MM, Knapp RG, Rush AJ, Mueller M, et al. ECT remission rates in psychotic versus nonpsychotic depressed patients: a report from CORE. J ECT. 2001;17(4):244–53.CrossRefPubMedGoogle Scholar
  19. 19.
    Meyers BS, Flint AJ, Rothschild AJ, Mulsant BH, Whyte EM, Peasley-Miklus C, et al. A double-blind randomized controlled trial of olanzapine plus sertraline vs olanzapine plus placebo for psychotic depression: the study of pharmacotherapy of psychotic depression (STOP-PD). Arch Gen Psychiatry. 2009;66(8):838–47.CrossRefPubMedPubMedCentralGoogle Scholar
  20. 20.
    Dols A, Bouckaert F, Sienaert P, Rhebergen D, Vansteelandt K, Ten Kate M, et al. Early- and late-onset depression in late life: a prospective study on clinical and structural brain characteristics and response to electroconvulsive therapy. Am J Geriatr Psychiatry. 2017;25(2):178–89.CrossRefPubMedGoogle Scholar
  21. 21.
    Haq AU, Sitzmann AF, Goldman ML, Maixner DF, Mickey BJ. Response of depression to electroconvulsive therapy: a meta-analysis of clinical predictors. J Clin Psychiatry. 2015;76(10):1374–84.CrossRefPubMedGoogle Scholar
  22. 22.
    Williams JH, O’Brien JT, Cullum S. Time course of response to electroconvulsive therapy in elderly depressed subjects. Int J Geriatr Psychiatry. 1997;12(5):563–6.CrossRefPubMedGoogle Scholar
  23. 23.
    Hamilton M. A rating scale for depression. J Neurol Neurosurg Psychiatry. 1960;23:56–62.CrossRefPubMedPubMedCentralGoogle Scholar
  24. 24.
    Tess AV, Smetana GW. Medical evaluation of patients undergoing electroconvulsive therapy. N Engl J Med. 2009;360(14):1437–44.CrossRefPubMedGoogle Scholar
  25. 25.
    Electroconvulsive therapy: guidelines for health authorities in British Columbia. British Columbia, Canada 2002. https://www.health.gov.bc.ca/library/publications/year/2002/MHA_ect_guidelines.pdf. Accessed 30 Mar 2019.
  26. 26.
    Sajatovic M, Strejilevich SA, Gildengers AG, Dols A, Al Jurdi RK, Forester BP, et al. A report on older-age bipolar disorder from the international society for bipolar disorders task force. Bipolar Disord. 2015;17(7):689–704.CrossRefPubMedPubMedCentralGoogle Scholar
  27. 27.
    Oudman E. Is electroconvulsive therapy (ECT) effective and safe for treatment of depression in dementia? A short review. J ECT. 2012;28(1):34–8.CrossRefPubMedGoogle Scholar
  28. 28.
    Hausner L, Damian M, Sartorius A, Frolich L. Efficacy and cognitive side effects of electroconvulsive therapy (ECT) in depressed elderly inpatients with coexisting mild cognitive impairment or dementia. J Clin Psychiatry. 2011;72(1):91–7.CrossRefPubMedGoogle Scholar
  29. 29.
    Kumar S, Mulsant BH, Liu AY, Blumberger DM, Daskalakis ZJ, Rajji TK. Systematic review of cognitive effects of electroconvulsive therapy in late-life depression. Am J Geriatr Psychiatry. 2016;24(7):547–65.CrossRefPubMedGoogle Scholar
  30. 30.
    Alexopoulos GS, Abrams RC, Young RC, Shamoian CA. Cornell scale for depression in dementia. Biol Psychiatry. 1988;23(3):271–84.CrossRefGoogle Scholar
  31. 31.
    Kaster TS, Daskalakis ZJ, Blumberger DM. Clinical effectiveness and cognitive impact of electroconvulsive therapy for schizophrenia: a large retrospective study. J Clin Psychiatry. 2017;78(4):e383–e9.CrossRefGoogle Scholar
  32. 32.
    Sanghani SN, Petrides G, Kellner CH. Electroconvulsive therapy (ECT) in schizophrenia: a review of recent literature. Curr Opin Psychiatry. 2018;31:213.CrossRefGoogle Scholar
  33. 33.
    Cohen CI, Meesters PD, Zhao J. New perspectives on schizophrenia in later life: implications for treatment, policy, and research. Lancet Psychiatry. 2015;2(4):340–50.CrossRefGoogle Scholar
  34. 34.
    Pier KS, Briggs MC, Pasculli RM, Kellner CH. Successful electroconvulsive therapy for major depression misdiagnosed as Alzheimer dementia. Am J Geriatr Psychiatry. 2012;20(10):909–10.CrossRefPubMedPubMedCentralGoogle Scholar
  35. 35.
    Acharya D, Harper DG, Achtyes ED, Seiner SJ, Mahdasian JA, Nykamp LJ, et al. Safety and utility of acute electroconvulsive therapy for agitation and aggression in dementia. Int J Geriatr Psychiatry. 2015;30(3):265–73.CrossRefGoogle Scholar
  36. 36.
    Kaster TS, Blumberger DM. Palliating severe refractory neuropsychiatric symptoms of dementia: is there a role for electroconvulsive therapy? Am J Geriatr Psychiatry. 2018;26:435.CrossRefGoogle Scholar
  37. 37.
    Blumberger DM, Seitz DP, Herrmann N, Kirkham JG, Ng R, Reimer C, et al. Low medical morbidity and mortality after acute courses of electroconvulsive therapy in a population-based sample. Acta Psychiatr Scand. 2017;136(6):583–93.CrossRefGoogle Scholar
  38. 38.
    Borisovskaya A, Bryson WC, Buchholz J, Samii A, Borson S. Electroconvulsive therapy for depression in Parkinson’s disease: systematic review of evidence and recommendations. Neurodegener Dis Manag. 2016;6(2):161–76.CrossRefGoogle Scholar
  39. 39.
    Factor SA, Molho ES, Brown DL. Combined clozapine and electroconvulsive therapy for the treatment of drug-induced psychosis in Parkinson’s disease. J Neuropsychiatry Clin Neurosci. 1995;7(3):304–7.CrossRefGoogle Scholar
  40. 40.
    Dessens FM, van Paassen J, van Westerloo DJ, van der Wee NJ, van Vliet IM, van Noorden MS. Electroconvulsive therapy in the intensive care unit for the treatment of catatonia: a case series and review of the literature. Gen Hosp Psychiatry. 2016;38:37–41.CrossRefPubMedGoogle Scholar
  41. 41.
    Mankad M. Informed consent for electroconvulsive therapy–finding balance. J ECT. 2015;31(3):143–6.CrossRefPubMedGoogle Scholar
  42. 42.
    Muzyka BC, Glass M, Glass OM. Oral health in electroconvulsive therapy: a neglected topic. J ECT. 2017;33(1):12–5.CrossRefPubMedGoogle Scholar
  43. 43.
    Waite J, Easton A. The ECT handbook. 3rd ed. London: Royal College of Psychiatrists; 2013.Google Scholar
  44. 44.
    Torring N, Sanghani SN, Petrides G, Kellner CH, Ostergaard SD. The mortality rate of electroconvulsive therapy: a systematic review and pooled analysis. Acta Psychiatr Scand. 2017;135(5):388–97.CrossRefPubMedGoogle Scholar
  45. 45.
    Castelli I, Steiner LA, Kaufmann MA, Alfille PH, Schouten R, Welch CA, et al. Comparative effects of esmolol and labetalol to attenuate hyperdynamic states after electroconvulsive therapy. Anesth Analg. 1995;80(3):557–61.PubMedPubMedCentralGoogle Scholar
  46. 46.
    Pandya M, Pozuelo L, Malone D. Electroconvulsive therapy: what the internist needs to know. Cleve Clin J Med. 2007;74(9):679–85.CrossRefPubMedGoogle Scholar
  47. 47.
    Uebaba S, Kitamura H, Someya T. A case of wrist fracture during modified electroconvulsive therapy. Psychiatry Clin Neurosci. 2009;63(6):772.PubMedGoogle Scholar
  48. 48.
    Bryson EO, Aloysi AS, Farber KG, Kellner CH. Individualized anesthetic management for patients undergoing electroconvulsive therapy: a review of current practice. Anesth Analg. 2017;124(6):1943–56.CrossRefPubMedGoogle Scholar
  49. 49.
    Deng ZD, Lisanby SH, Peterchev AV. Effect of anatomical variability on electric field characteristics of electroconvulsive therapy and magnetic seizure therapy: a parametric modeling study. IEEE Trans Neural Syst Rehabil Eng. 2015;23(1):22–31.CrossRefPubMedGoogle Scholar
  50. 50.
    Sienaert P. Bifrontal, bitemporal and right unilateral ECT electrode placement are similarly effective for reducing depressive symptoms. Evid Based Ment Health. 2010;13(3):85.CrossRefPubMedGoogle Scholar
  51. 51.
    Dunne RA, McLoughlin DM. Systematic review and meta-analysis of bifrontal electroconvulsive therapy versus bilateral and unilateral electroconvulsive therapy in depression. World J Biol Psychiatry. 2012;13(4):248–58.CrossRefPubMedGoogle Scholar
  52. 52.
    Kellner CH, Husain MM, Knapp RG, McCall WV, Petrides G, Rudorfer MV, et al. Right unilateral Ultrabrief pulse ECT in geriatric depression: phase 1 of the PRIDE study. Am J Psychiatry. 2016;173(11):1101–9.CrossRefPubMedGoogle Scholar
  53. 53.
    Tor PC, Bautovich A, Wang MJ, Martin D, Harvey SB, Loo C. A systematic review and meta-analysis of brief versus Ultrabrief right unilateral electroconvulsive therapy for depression. J Clin Psychiatry. 2015;76(9):e1092–8.CrossRefPubMedGoogle Scholar
  54. 54.
    Mankad MV, Beyer JL, Weiner RD, Krystal A. Clinical manual of electroconvulsive therapy. American Psychiatric Assoc Pub; 2010. https://www.appi.org/Clinical_Manual_of_Electroconvulsive_Therapy. Accessed 30 Mar 2019.
  55. 55.
    Semkovska M, Landau S, Dunne R, Kolshus E, Kavanagh A, Jelovac A, et al. Bitemporal versus high-dose unilateral twice-weekly electroconvulsive therapy for depression (EFFECT-Dep): a pragmatic, randomized, non-inferiority trial. Am J Psychiatry. 2016;173(4):408–17.CrossRefPubMedGoogle Scholar
  56. 56.
    Charlson F, Siskind D, Doi SA, McCallum E, Broome A, Lie DC. ECT efficacy and treatment course: a systematic review and meta-analysis of twice vs thrice weekly schedules. J Affect Disord. 2012;138(1–2):1–8.CrossRefPubMedGoogle Scholar
  57. 57.
    Petrides G, Braga RJ, Fink M, Mueller M, Knapp R, Husain M, et al. Seizure threshold in a large sample: implications for stimulus dosing strategies in bilateral electroconvulsive therapy: a report from CORE. J ECT. 2009;25(4):232–7.CrossRefPubMedPubMedCentralGoogle Scholar
  58. 58.
    Prudic J, Haskett RF, McCall WV, Isenberg K, Cooper T, Rosenquist PB, et al. Pharmacological strategies in the prevention of relapse after electroconvulsive therapy. J ECT. 2013;29(1):3–12.PubMedPubMedCentralGoogle Scholar
  59. 59.
    Milev RV, Giacobbe P, Kennedy SH, Blumberger DM, Daskalakis ZJ, Downar J, et al. Canadian network for mood and anxiety treatments (CANMAT) 2016 clinical guidelines for the Management of Adults with major depressive disorder: section 4. Neurostimulation treatments. Can J Psychiatr. 2016;61(9):561–75.CrossRefGoogle Scholar
  60. 60.
    Sienaert P, Peuskens J. Anticonvulsants during electroconvulsive therapy: review and recommendations. J ECT. 2007;23(2):120–3.CrossRefPubMedGoogle Scholar
  61. 61.
    Dolenc TJ, Rasmussen KG. The safety of electroconvulsive therapy and lithium in combination: a case series and review of the literature. J ECT. 2005;21(3):165–70.CrossRefPubMedGoogle Scholar
  62. 62.
    Thirthalli J, Harish T, Gangadhar BN. A prospective comparative study of interaction between lithium and modified electroconvulsive therapy. World J Biol Psychiatry. 2011;12(2):149–55.CrossRefPubMedGoogle Scholar
  63. 63.
    Nordenskjold A, von Knorring L, Ljung T, Carlborg A, Brus O, Engstrom I. Continuation electroconvulsive therapy with pharmacotherapy versus pharmacotherapy alone for prevention of relapse of depression: a randomized controlled trial. J ECT. 2013;29(2):86–92.CrossRefPubMedGoogle Scholar
  64. 64.
    Nothdurfter C, Eser D, Schule C, Zwanzger P, Marcuse A, Noack I, et al. The influence of concomitant neuroleptic medication on safety, tolerability and clinical effectiveness of electroconvulsive therapy. World J Biol Psychiatry. 2006;7(3):162–70.CrossRefPubMedGoogle Scholar
  65. 65.
    Arumugham SS, Thirthalli J, Andrade C. Efficacy and safety of combining clozapine with electrical or magnetic brain stimulation in treatment-refractory schizophrenia. Expert Rev Clin Pharmacol. 2016;9(9):1245–52.CrossRefPubMedGoogle Scholar
  66. 66.
    Brady M, Kinn S, Stuart P. Preoperative fasting for adults to prevent perioperative complications. Cochrane Database Syst Rev. 2003;4:CD004423.Google Scholar
  67. 67.
    Obbels J, Verwijk E, Bouckaert F, Sienaert P. ECT-related anxiety: a systematic review. J ECT. 2017;33(4):229–36.CrossRefPubMedGoogle Scholar
  68. 68.
    Geduldig ET, Kellner CH. Electroconvulsive therapy in the elderly: new findings in geriatric depression. Curr Psychiatry Rep. 2016;18(4):40.CrossRefPubMedGoogle Scholar
  69. 69.
    Porter RJ, Douglas K, Knight RG. Monitoring of cognitive effects during a course of electroconvulsive therapy: recommendations for clinical practice. J ECT. 2008;24(1):25–34.CrossRefPubMedGoogle Scholar
  70. 70.
    Folstein MF, Folstein SE, McHugh PR. “Mini-mental state”. A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res. 1975;12(3):189–98.CrossRefPubMedPubMedCentralGoogle Scholar
  71. 71.
    van Schaik AM, Comijs HC, Sonnenberg CM, Beekman AT, Sienaert P, Stek ML. Efficacy and safety of continuation and maintenance electroconvulsive therapy in depressed elderly patients: a systematic review. Am J Geriatr Psychiatry. 2012;20(1):5–17.CrossRefGoogle Scholar
  72. 72.
    Shelef A, Mazeh D, Berger U, Baruch Y, Barak Y. Acute electroconvulsive therapy followed by maintenance electroconvulsive therapy decreases hospital re-admission rates of older patients with severe mental illness. J ECT. 2015;31(2):125–8.CrossRefGoogle Scholar
  73. 73.
    Kellner CH, Husain MM, Knapp RG, McCall WV, Petrides G, Rudorfer MV, et al. A novel strategy for continuation ECT in geriatric depression: phase 2 of the PRIDE study. Am J Psychiatry. 2016;173(11):1110–8.CrossRefGoogle Scholar
  74. 74.
    Riva-Posse P, Hermida AP, McDonald WM. The role of electroconvulsive and neuromodulation therapies in the treatment of geriatric depression. Psychiatr Clin North Am. 2013;36(4):607–30.CrossRefGoogle Scholar
  75. 75.
    McClintock SM, Brandon AR, Husain MM, Jarrett RB. A systematic review of the combined use of electroconvulsive therapy and psychotherapy for depression. J ECT. 2011;27(3):236–43.CrossRefPubMedPubMedCentralGoogle Scholar
  76. 76.
    Medical Advisory Secretariat. Repetitive transcranial magnetic stimulation for the treatment of major depressive disorder: an evidence-based analysis. Ont Health Technol Assess Ser. 2004;4(7):1–98.PubMedPubMedCentralGoogle Scholar
  77. 77.
    Rossi S, Hallett M, Rossini PM, Pascual-Leone A. Safety of TMSCG. Safety, ethical considerations, and application guidelines for the use of transcranial magnetic stimulation in clinical practice and research. Clin Neurophysiol. 2009;120(12):2008–39.CrossRefPubMedPubMedCentralGoogle Scholar
  78. 78.
    Jorge RE, Moser DJ, Acion L, Robinson RG. Treatment of vascular depression using repetitive transcranial magnetic stimulation. Arch Gen Psychiatry. 2008;65(3):268–76.CrossRefGoogle Scholar
  79. 79.
    Hizli Sayar G, Salcini C, Tarhan N. Transcranial magnetic stimulation in a depressive patient with cardiac pacemaker. J ECT. 2016;32(3):e22–3.CrossRefGoogle Scholar
  80. 80.
    Perera T, George MS, Grammer G, Janicak PG, Pascual-Leone A, Wirecki TS. The clinical TMS Society consensus review and treatment recommendations for TMS therapy for major depressive disorder. Brain Stimul. 2016;9(3):336–46.CrossRefPubMedPubMedCentralGoogle Scholar
  81. 81.
    Ren J, Li H, Palaniyappan L, Liu H, Wang J, Li C, Rossini PM. Repetitive transcranial magnetic stimulation versus electroconvulsive therapy for major depression: a systematic review and meta-analysis. Prog Neuropsychopharmacol. Biol Psychiatry. 2014;51:181–9.CrossRefPubMedGoogle Scholar
  82. 82.
    NICE. Repetitive transcranial magnetic stimulation for depression. December 2015. https://www.nice.org.uk/guidance/ipg542/resources/repetitive-transcranial-magnetic-stimulation-for-depression-pdf-1899871923433669. Accessed 30 Mar 2019.
  83. 83.
    Janicak PG, Nahas Z, Lisanby SH, Solvason HB, Sampson SM, McDonald WM, et al. Durability of clinical benefit with transcranial magnetic stimulation (TMS) in the treatment of pharmacoresistant major depression: assessment of relapse during a 6-month, multisite, open-label study. Brain Stimul. 2010;3(4):187–99.CrossRefPubMedGoogle Scholar
  84. 84.
    Robinson RG, Tenev V, Jorge RE. Citalopram for continuation therapy after repetitive transcranial magnetic stimulation in vascular depression. Am J Geriatr Psychiatry. 2009;17(8):682–7.CrossRefPubMedPubMedCentralGoogle Scholar
  85. 85.
    Galletly CA, Clarke P, Carnell BL, Gill S. A clinical repetitive transcranial magnetic stimulation service in Australia: 6 years on. Aust N Z J Psychiatry. 2015;49(11):1040–7.CrossRefPubMedGoogle Scholar
  86. 86.
    Berman RM, Cappiello A, Anand A, Oren DA, Heninger GR, Charney DS, et al. Antidepressant effects of ketamine in depressed patients. Biol Psychiatry. 2000;47(4):351–4.CrossRefPubMedGoogle Scholar
  87. 87.
    Szymkowicz SM, Finnegan N, Dale RM. Failed response to repeat intravenous ketamine infusions in geriatric patients with major depressive disorder. J Clin Psychopharmacol. 2014;34(2):285–6.CrossRefPubMedPubMedCentralGoogle Scholar
  88. 88.
    Srivastava S, Gangwar RS, Kumar A. Safety and efficacy of ketamine infusion in late onset depression, and conversion to treatment response. Indian J Psychiatry. 2015;57(3):328–9.CrossRefPubMedPubMedCentralGoogle Scholar
  89. 89.
    Medeiros da Frota Ribeiro C, Riva-Posse P. Use of ketamine in elderly patients with treatment-resistant depression. Curr Psychiatry Rep. 2017;19(12):107.CrossRefPubMedGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2019

Authors and Affiliations

  • Lisa A. McMurray
    • 1
  • Barbara Deren
    • 2
  1. 1.University of Ottawa, Royal Ottawa Mental Health CentreOttawaCanada
  2. 2.Resident in PsychiatryUniversity of Ottawa, The Ottawa Hospital (General Campus)OttawaCanada

Personalised recommendations